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1. Introduction
Alpha-1	antitrypsin	(AAT)	deficiency	is	the	
most	common	genetic	disorder	in	the	adult	popu-
lation	of	European	descent.	However,	it	is	usually	
diagnosed	late,	in	the	fifth	decade	of	life,	typically	
due	to	advanced	changes	in	the	respiratory	system	
or	in	the	liver.	In	a	large	number	of	patients	the	
deficiency	remains	undiagnosed.
Initial	 diagnosis	 towards	 inherited	AAT	
deficiency	should	be	a	part	of	standard	medical	
procedure	for	all	patients	with	chronic	respiratory	
tract	diseases	marked	by	persistent	airway	obs-
truction,	especially	for	patients	with	diagnosed	
COPD,	bronchial	asthma	with	non-fully	 rever-
sible	airway	obstruction	and	bronchiectasis,	as	
well	as	for	children	with	symptoms	of	cholestatic	
jaundice,	cirrhosis	and	adults	with	non-alcoho-
lic	 liver	cirrhosis.	The	range	of	 indications	 for	
diagnostic	procedure	for	other	extrapulmonary	
diseases	of	adulthood	and	in	pediatrics	as	well	
as	knowledge	of	optimal	diagnostic	algorithm,	
including	genotyping	and	phenotyping	methods,	
also	require	urgent	dissemination	in	the	medical	
community.	Awareness	of	means	of	active	pre-
vention	of	acute	and	chronic	respiratory	diseases	
(strict	prevention	of	active	and	passive	tobacco	
smoking,	air	pollution	in	the	workplace	and	at	
home,	preemptive	vaccination)	 as	well	 as	 an	
evaluation	of	 effectiveness	of	 and	 indications	
for	 intravenous	augmentation	 therapy	 remain	
important	 issues	 in	care	of	patients	with	AAT	
deficiency	(Table	1).	
This	document	is	an	update	to	the	“Standards	
for	diagnosis	and	care	of	patients	with	inherited	
alpha-1	antitrypsin	deficiency”	prepared	in	2010	
by	a	working	group	then	established	by	the	Polish	
Respiratory	Society.	
1.1. Biological significance of alpha-1 
antitrypsin
Alpha-1	antitrypsin	is	a	glycoprotein	with	a	
molecular	weight	of	55	kDa	composed	of	a	single	
polypeptide	chain	 (394	amino	acids)	which	 is	
subject	 to	a	complex	process	of	glycosylation.	
This	protein	is	synthesized	mainly	in	the	liver	
and	subsequently	secreted	into	the	bloodstream.	
AAT	belongs	to	the	serpin	family	and	is	one	of	
the	most	 important	plasma	and	 tissue	 serine	
protease	inhibitors	in	the	human	body,	effecti-
vely	inhibiting	the	action	of	multiple	enzymes	
(neutrophil	elastase,	proteinase	3,	cathepsin	G,	
trypsin).	
AAT	plays	a	significant	role	in	maintaining	
the	protease-antiprotease	balance	under	in	vivo	
conditions.	This	inhibitor	is	an	important	element	
of	the	anti-elastase	shield	in	the	lungs,	protecting	
that	organ’s	tissue	from	uncontrolled,	destructive	
influence	of	proteolytic	enzymes.	Low	levels	of	
AAT	 in	 the	 respiratory	system	 lead	 to	gradual	
and	 irreversible	decline	 in	 the	elasticity	of	 the	
lungs.	Overactivity	of	neutrophil	elastase	causes	
degradation	of	elastin	(a	primary	component	of	
elastic	fibers)	as	well	as	of	other	components	of	
the	extracellular	matrix	in	the	lower	respiratory	
tract.	Exposure	to	inhaled	irritants,	particularly	
tobacco	smoke,	 stimulates	 the	development	of	
a	 local	 inflammatory	process	 in	 the	respiratory	
tract,	 including	 release	 of	proteases	 and	 free	
oxygen	radicals.	Their	interaction	with	AAT	pro-
motes	formation	of	inactive	and/or	polymerized	
forms	of	this	protein	which	are	characterized	by	
pro-inflammatory	activity.	
1.2. Molecular basis of alpha-1 antitrypsin 
deficiency 
AAT	deficiency	is	a	genetically	determined	
disorder	caused	by	a	mutation	of	the	SERPINA1 
gene	 (previously	designated	PI,	protease	 inhi-
bitor),	 located	on	 the	 long	arm	of	chromosome	
14.	So	far,	over	130	genetic	variants	(alleles)	of	
this	 gene	have	been	 identified,	which	encode	
AAT	protein	variants	with	different	quantitati-
ve	 (concentration	 in	 the	 serum)	or	qualitative	
(biological	activity)	characteristics.	Phenotypic	
AAT	protein	variants	have	been	classified	 in	a	
system	referred	to	as	the	PI	(protease	inhibitor)	
system.	This	classification	was	created	using	the	
isoelectric	 focusing	 technique,	which	 involves	
separating	protein	in	polyacrylamide	gels	with	an	
appropriate	pH	gradient.	As	a	consequence	of	the	
SERPINA1	gene	mutation	there	are	differences	in	
amino	acid	composition	of	each	protein	variant,	
which	result	in	changes	in	isoelectric	point	and	
electrophoretic	mobility	in	the	gel.	This	pheno-
menon	is	used	to	identify	AAT	phenotype.	AAT	
variants	marked	with	 the	 initial	 letters	of	 the	
alphabet	are	characterized	by	 lower	pH	of	 the	
isoelectric	point	(a	change	to	a	more	acidic	amino	
Table 1. Indications for intravenous augmentation therapy 
with alpha-1 antitrypsin (all listed)
Severe inherited AAT deficiency emphysema
Alpha-1 antitrypsin concentration in the serum ≤ 11 µmol/L,
FEV1 after bronchodilator administration = 30−65% predicted
or annual decline in FEV1 value ≥ 50 mL/year
Never-smokers and ex-smokers only
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acid)	and	a	greater	migration	distance	in	the	gel;	
variants	with	a	more	alkaline	 isoelectric	point,	
less	mobile	 -	 are	marked	with	 the	final	 letters	
of	the	alphabet.	Ordinarily,	several	AAT	protein	
bands	become	visible	during	 electrophoretic	
separation,	which	is	due	to	varying	degree	of	its	
glycosylation.	The	most	common	normal	variants	
are	characterized	by	intermediate	electrophoretic	
mobility	and	are	marked	with	the	letter	M,	M1A	
and	M1V	respectively	(Ala213Val)	as	well	as	clini-
cally	insignificant	M2	(Arg101His),	M3	(Glu376Asp)	
and	M4	(Asp256Val).
For	 clinical	 and	practical	 purposes	AAT	
variants	have	been	divided	 into	4	classes,	de-
pending	 on	 concentration	 and	 function	 of	 a	
given	type	in	the	plasma.	The	family	of	normal	
AAT	variants	is	designated	PI*M.	These	are	the	
most	 common	alleles	 of	 the	AAT	gene	 in	 the	
European	population	(present	in	approximately	
95%	of	people)	which	ensure	normal	levels	and	
functioning	of	this	inhibitor	in	the	plasma.	De-
ficiency	variants	constitute	another	class,	whose	
protein	products	 are	 subject	 to	 intracellular	
accumulation	or	degradation	in	the	liver,	which	
leads	to	a	significant	decrease	in	AAT	levels	in	
the	bloodstream.	Two	most	common	deficiency	
alleles,	PI*Z	and	PI*S,	which	condition	severe	
AAT	deficiency,	can	be	found	within	this	group.	
Alleles	devoid	of	 expression	 (so-called	 “null”	
alleles)	constitute	another	class.	These	are	rare	
genetic	variants	of	AAT,	whose	protein	products	
are	not	detected	in	the	bloodstream.	Genetic	va-
riants	of	AAT	which	encode	dysfunctional	protein	
form	the	final	class.
The	Z	variant	of	the	SERPINA1	gene	(very	
slow	migration)	is	determined	by	a	single	point	
mutation	 leading	 to	 substitution	 of	 glutamic	
acid	with	 lysine	 at	position	342	 (Glu342>Lys)	
and	as	a	result	to	loss	of	stability	of	the	spatial	
structure	of	the	protein	(Z-AAT),	which	polyme-
rizes	while	still	within	hepatocytes.	The	Z-AAT	
protein	is	characterized	by	low	ability	to	inhibit	
proteases	in	the	bloodstream	and	in	tissues.	In	
patients	with	the	PI*ZZ	genotype,	that	is,	with	
two	PI*Z	deficiency	alleles,	the	concentration	
of	alpha-1	antitrypsin	in	 the	serum	is	10-15%	
of	normal.	
The	protein	product	of	the	S	allele	(slow	mi-
gration)	is	characterized	by	a	substitution	of	gluta-
mic	acid	with	valine	at	position	264	(Glu264>Val),	
which	causes	the	newly	formed	S-AAT	protein	to	
be	degraded	while	still	within	liver	cells.	The	AAT	
concentration	in	the	serum	of	PI*SS	homozygotes	
is	approximately	40%	lower	than	in	individuals	
with	normal	PI*MM	genotype.	
2. Epidemiology and clinical significance of 
inherited alpha-1 antitrypsin deficiency
2.1. Global data
AAT	deficiency	is	one	of	the	most	common	
inherited	diseases	in	Europe.	The	severe	form	of	
AAT	deficiency	(PI*ZZ)	has	an	estimated	preva-
lence	of	1	in	1500	to	1	in	3500	live	births	in	most	
populations;	a	decreasing	gradient	of	prevalence	
of	PI*Z	variant	is	observed	north	to	south,	and	of	
PI*S	variant	west	to	east	of	Europe.	
According	 to	data	 from	58	countries,	pu-
blished	 in	2002,	 the	 total	number	of	patients	
with	AAT	deficiency	(taking	PI	phenotype:	ZZ,	
SZ	and	SS	 into	account)	was	estimated	at	3.4	
million	 in	 countries	 in	northern	and	western	
Europe.	Prevalence	of	PI*Z	allele	is	higher,	at	14	
in	1000	on	average,	while	PI*ZZ	homozygotes	
have	a	prevalence	of	1	in	5000.	A	review	of	68	
selected	epidemiological	studies	conducted	in	21	
European	countries	on	a	group	of	75,390	indivi-
duals	in	total	estimates	the	average	prevalence	of	
severe	AAT	deficiency	phenotype	(PI*ZZ)	in	the	
European	population	at	1:4727.	
Published	results	are	inconsistent	and	the	dif-
ferences	within	the	same	populations	stem	from	
non-random	sampling.	High	prevalence	of	PI*Z	
allele	was	observed	in	northern	and	western	Swe-
den	(2.3−3.2%),	Estonia	and	Lithuania,	as	well	as	
among	the	Danes.	The	PI*Z	allele	is	somewhat	ra-
rer	(2−2.25%)	in	northern	France	(Normandy	and	
Brittany),	Ireland	and	southern	England.	The	rest	
of	Europe	is	characterized	by	a	prevalence	of	the	
Z	variant	of	less	than	2%.	The	lowest	prevalence	
of	 the	Z	variant	was	observed	in	southern	Italy	
and	in	Russia.	Prevalence	of	PI*ZZ	homozygotes	
is	theoretically	equal	to	the	square	of	prevalence	
of	the	Z	allele.	Distribution	of	PI*ZZ	homozygotes	
decreases	from	the	north-east	(1:500−5,000)	in	the	
south-western	direction	(1:1000−90,000).
2.2. Polish data
Polish	data	concerning	prevalence	of	AAT	
deficiency	is	scarce.	Most	analyses	concern	adults	
and	were	conducted	in	relatively	small	groups,	
encompassing	2653	individuals	in	total.	Based	on	
the	analysis	of	available	data,	prevalence	of	the	
PI*S	and	PI*Z	allele	is	14.5/1,000	and	10.9/1,000,	
respectively.	This	allows	to	estimate	the	preva-
lence	of	 the	PI*ZZ	phenotype	at	1/9110.	4,189	
individuals	with	the	described	phenotype	could	
therefore	be	expected	 in	 the	Polish	population	
of	38	million.
Recently,	a	study	of	prevalence	of	the	main	
deficiency	 alleles	 has	 been	 conducted	 via	 a	
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screening	of	a	population	of	5,000	neonates	from	
Warsaw	and	the	Mazovia	region.	Initial	results,	
derived	from	genotyping	in	a	group	of	658	chil-
dren,	indicate	a	much	higher	prevalence	of	the	
main	deficiency	genotype	PI*ZZ	of	1/5345,	which	
would	correspond	to	estimated	7000	individuals	
with	severe	deficiency	(PI*ZZ)	in	Poland.
3. Diagnosis of inherited alpha-1 antitrypsin 
deficiency
3.1. Diagnostic methods — advantages and 
disadvantages
A	complete	 diagnosis	 of	AAT	deficiency	
is	based	on	a	combination	of	quantitative	 (me-
asurement	of	AAT	concentration	 in	 the	serum)	
and	qualitative	methods	which	allow	to	identify	
the	variant	of	the	AAT	protein	(phenotyping)	or	
the	SERPINA1	gene	(genotyping,	DNA	sequence	
analysis).	Certain	diagnosis	 of	 inherited	AAT	
deficiency	always	 requires	 confirming	 it	 on	a	
molecular	 level.	A	 clear	 identification	of	 the	
protein	phenotype	or	 the	genotype	 is	 therefore	
necessary.	 It	 is	 recommended	 that	a	diagnosis	
of	AAT	deficiency	be	confirmed	by	at	least	two	
diagnostic	methods:
1)		 measurement	of	AAT	concentration	 in	 the	
serum	+	AAT	protein	phenotyping,
2)		 measurement	of	AAT	concentration	 in	 the	
serum	+	genotyping,	
3)		 AAT	protein	phenotyping	+	genotyping.
The	above	rule	allows	for	certain	diagnosis	
of	 the	most	 common	deficiency	variants.	 If	 a	
rare	or	atypical	variant	of	AAT	gene	mutation	
is	suspected,	DNA	sequence	analysis	should	be	
performed.	
3.1.1. Measurement of AAT concentration
An	initial	test	performed	for	individuals	with	
suspected	deficiency	of	 this	protease	 inhibitor	
is	 a	measurement	of	 concentration	of	 alpha-1	
antitrypsin	in	the	blood	serum/plasma	using	co-
lorimetric	or	 immunological	methods.	 Immuno-
nephelometry	is	the	method	of	choice	due	to	high	
sensitivity	of	measurement.	AAT	concentration	is	
typically	expressed	in	milligrams	per	deciliter	(mg/
dL)	or	millimoles	per	liter	(µmol/L	or	µM).	Normal	
levels	of	AAT	concentration	in	the	serum	in	he-
althy	individuals	are	between	20−39	µM	which,	
when	using	 a	modern	 immunonephelometric	
method,	corresponds	to	 levels	between	83−220	
mg/dL,	and	when	using	an	older	rocket	immuno-
electrophoresis	method	—	150−330	mg/dL.	
Observing	a	decreased	AAT	level	in	the	tested	
individual	(≤	100	mg/dL)	is	an	absolute	indication	
to	continue	diagnosis	and	perform	further	quali-
tative	tests.	They	should	also	be	considered	for	
an	individual	with	a	low	normal	AAT	concentra-
tion	(90−130	mg/dL	or	12−35 µM),	especially	in	
case	of	concomitant	pathology	of	the	respiratory	
system	or	the	liver.	
AAT	belongs	to	the	acute-phase	protein	gro-
up,	hence	 its	concentration	can	be	elevated	 in	
the	course	of	multiple	disease	processes,	even	
in	case	of	 concomitant	deficiency.	 In	order	 to	
increase	diagnostic	accuracy	and	reduce	the	risk	
of	 false	negative	 results,	 it	 is	 recommended	 to	
simultaneously	determine	 the	concentration	of	
AAT	and	the	acute-phase	protein	(CRP).	
3.1.2. Phenotyping
The	method	of	identifying	the	AAT	protein	
variant	 through	 isoelectric	 focusing	 (IEF)	 in	 
a	polyacrylamide	gel	 (pH	gradient	4.2–4.9)	 is	
a	“gold	standard”	 in	diagnosing	 the	deficiency.	
Small	 changes	 in	 the	electrolytic	dissociation	
constant	of	the	protein	allow	to	differentiate	every	
AAT	variant	except	the	“null”	variants.	
This	method	 is	 technically	 fairly	difficult,	
time-consuming	and,	due	 to	complex	microhe-
terogeneity	stemming	from	glycosylation	as	well	
as	 the	 considerable	number	of	AAT	variants,	
requires	substantial	experience	and	 the	ability	
to	analyze	results.	It	should	be	remembered	that	
phenotyping	does	not	allow	to	identify	mutations	
of	the	AAT	gene	which	are	not	expressed.	There	
are	also	rare	variants	of	the	serine	protease	inhibi-
tor	with	identical	or	only	slightly	different	values	
of	the	isoelectric	point.	Correct	interpretation	of	
results	of	electrophoresis	of	these	phenotypes	pre-
sents	considerable	difficulty.	A	result	indicating	
the	presence	of	a	deficiency	variant	of	the	protein	
requires	confirmation	by	another	diagnostic	me-
thod,	quantitative	or	qualitative	(as	noted	above).	
3.1.3. Genotyping
Genotyping	allows	to	directly	identify	irre-
gularities	within	the	AAT	gene,	that	is,	mutations	
in	the	SERPINA1	gene	locus	responsible	for	the	
emergence	of	the	deficiency.	The	most	commonly	
used	diagnostic	methods	allow	to	identify	only	
two	most	frequently	occurring	deficiency	muta-
tions	—	PI*Z	and	PI*S.	
The	basis	 for	most	methods	of	 identifying	
mutations	 is	 the	analysis	of	 appropriate	DNA	
region	replicated	in	a	polymerase	chain	reaction	
(PCR).	The	primary	material	obtained	 from	the	
patient	in	order	to	perform	a	genetic	analysis	is	
DNA	isolated	from	peripheral	blood	leukocytes	
or,	alternatively,	from	other	tissue	cells	(oral	mu-
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Figure 1. Proposed diagnostic algorithm for suspected severe alpha-1 antitrypsin deficiency or other mutations causing quantitative deficiency, 
including: AAT protein phenotyping (see section 3.1.2), AAT genotyping (see section 3.1.3) and DNA sequencing (see section 3.1.4)
cosal	epithelial	cells),	as	well	as	a	blood	sample	
on	filter	paper.
3.1.4. DNA sequence analysis
DNA	sequence	analysis	allows	 to	discover	
nucleotide	mutations,	 that	 is	 to	determine	 the	
genetic	variants	in	the	analyzed	DNA	fragment.	
It	is	an	expensive	and	time-consuming	method,	
requiring	 replication	of	SERPINA1	 gene	exons	
using	PCR	technique	and	their	sequencing.	This	
method	is	not	routinely	used	in	diagnosing	AAT	
deficiency;	it	is	only	used	in	case	a	rare	or	new	
variant	of	alpha-1	antitrypsin	is	suspected	(aty-
pical	IEF	pattern,	low	AAT	concentration	with	no	
PI*Z	or	PI*S	mutations).
3.2. Recommended diagnostic scheme for 
inherited alpha-1 antitrypsin deficiency
Measurement	of	AAT	concentration	in	peri-
pheral	blood	serum	is	the	initial	diagnostic	test.	
It	is	recommended	to	simultaneously	estimate	
CRP	concentration	in	order	to	exclude	an	active	acu-
te-phase	response	and	avoid	false	negative	results.	It	
should	be	remembered	that	during	an	inflammatory	
response	with	activation	of	acute-phase	protein,	inc-
luding	CRP,	AAT	concentration	will	also	be	elevated	
and	obtained	result	will	be	non-diagnostic.
AAT	concentration	below	100	mg/dL	 is	an	
indication	 to	 continue	diagnosis	 and	perform	 
a	qualitative	analysis	of	the	AAT	protein	(pheno-
typing)	or	the	SERPINA1	gene	(genotyping).	This	
procedure	allows	for	correct	diagnosis	in	nearly	
96%	of	patients	with	severe	AAT	deficiency	and	
patients	with	rare	mutations	implying	quantitati-
ve	AAT	deficiency.	It	should	be	remembered	that	
analysis	using	the	genotyping	method	typically	
allows	to	identify	only	two	main	deficiency	alle-
les	(PI*Z	and	PI*S)	and	does	not	preclude	other	
mutations.	Phenotyping	allows	to	identify	most	
deficiency	variants	of	the	AAT	protein.	
If	definite	diagnosis	at	 this	point	 is	 impos-
sible,	if	rare	or	new	AAT	variants	are	suspected,	
sequence	analysis	of	the	SERPINA1	gene,	that	is	
sequencing	of	the	AAT	gene,	is	necessary.	
This	usually	allows	 for	definite	diagnosis	
and	ends	diagnostic	procedure	 for	 severe	AAT	
deficiency.	
Proposed	diagnostic	algorithm	for	suspected	
severe	alpha-1	antitrypsin	deficiency	or	other	mu-
tations	causing	quantitative	deficiency,	including:	
AAT	protein	phenotyping	(see	section	3.1.2),	AAT	
genotyping	(see	section	3.1.3)	and	DNA	sequen-
cing	(see	section	3.1.4),	is	presented	in	Figure	1.
In	some	clinically	appropriate	cases,	espe-
cially	when	rarer	 forms	of	alpha-1	antitrypsin	
deficiency	caused	by	a	qualitative	mutation	im-
plying	 low	or	no	biological	activity	of	 the	AAT	
protein	are	suspected,	phenotyping	and/or	sequ-
encing	of	the	SERPINA1	gene	is	necessary.	Normal	
result	of	measurement	of	AAT	concentration	in	
the	serum	does	not	preclude	AAT	deficiency	in	
these	cases.	
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4. Treatment and care of patients with inherited 
alpha-1 antitrypsin deficiency
4.1. Hepatological problems in children 
Accumulation	of	AAT	 in	hepatocytes	and	
liver	damage	 is	possible	 from	the	moment	 the	
liver	begins	to	synthesize	the	protein.	It	is	charac-
teristic	for	the	PI*ZZ	phenotype.	The	argument	of	
AAT	deficiency	as	disease	of	the	fetus	is	supported	
by	early	emergence	of	its	symptoms	in	the	first	
days	or	weeks	of	 life,	 low	birth	weight	of	most	
neonates	with	liver	damage	and	described	cases	
of	concomitant	AAT	deficiency	and	biliary	atresia.
In	most	cases	cholestatic	jaundice	prolonged	
beyond	4th-8th	week	of	 life	and	acholic	stools	
are	 the	first	symptoms	of	 the	disease.	Physical	
examination	 typically	 reveals	 increased	 liver	
span,	while	 laboratory	 tests	 show	 increased	
transaminase	activity	and	bilirubin	concentration	
with	predominance	of	bound	fraction.	Occasio-
nally,	diagnosis	 is	prompted	by	bleeding	 from	
the	neonate’s	umbilicus	or	gastrointestinal	tract.	
AAT	deficiency	is	often	not	diagnosed	until	the	
child	 is	older,	whereupon	hepatomegaly,	 incre-
ased	 transaminase	activity	or	 jaundice	are	 the	
first	alarming	symptoms,	which	complicate	the	
course	of	 the,	often	 infective,	underlying	dise-
ase.	The	disease	may	first	manifest	itself	at	any	
age	through	portal	hypertension	complications:	
splenomegaly,	hypersplenism,	ascites,	bleeding	
esophageal	varices	and	encephalopathy.	Singular	
cases	of	hepatocellular	carcinoma	occurring	 in	
children	have	also	been	described.	
The	 course	 of	 the	disease	 in	 children	 is	
unpredictable.	Adverse	prognostic	 factors	 are	
constantly	being	sought	in	order	to	identify	the	
group	of	patients	with	 increased	 risk	of	 liver	
cirrhosis.	It	is	thought	that	if	increased	transami-
nase	levels	and	conjugated	hyperbilirubinemia	in	
neonates	are	not	accompanied	by	neither	jaundice	
nor	hepatomegaly,	prognosis	is	better.	Conversely,	
the	following	are	considered	adverse	prognostic	
factors	in	infancy:	jaundice	prolonged	beyond	6	
weeks,	increased	transaminase	activity	compared	
to	the	group	with	good	prognosis	and	severe	chan-
ges	 in	diagnostic	 liver	biopsy.	 In	patients	with	
portal	hypertension	and	liver	cirrhosis	in	some	
cases	clinical	condition	remains	stable	long-term.	
Oher	 than	 liver	 transplantation,	 there	are	
currently	no	causal	 treatment	options	 for	AAT	
deficiency.	Preventive	methods	 applicable	 to	
children	 include	breastfeeding	or	 soy	 formula	
feeding,	no	exposure	to	tobacco	smoke,	plasma	
infusions	before	planned	surgical	procedures.	
Ursodeoxycholic	acid	(UDCA)	preparations	and	
fat-soluble	vitamins	 are	used	 in	 treatment	of	
cholestasis.	There	are	 reports	of	vitamin	E	be-
ing	effective	 in	early	 infancy.	 In	case	of	portal	
hypertension	 in	 the	 course	of	 liver	 cirrhosis,	
endoscopic	 treatment	of	 esophageal	varices	 is	
effective,	and	 in	patients	with	 increasing	 liver	
dysfunction	-	its	transplantation	is	effective.	In-
dications	 for	 liver	 transplantation	do	not	differ	
from	those	in	liver	damage	due	to	other	causes:	
coagulation	disorders,	hypoalbuminemia,	ble-
eding	esophageal	varices.	AAT	deficiency	is	the	
second	most	frequent,	after	biliary	atresia,	cause	
of	liver	transplantations	in	children.	One	of	the	
parents	is	usually	the	donor,	and	the	prognosis	is	
good.	AAT	phenotype	following	transplantation	
is	consistent	with	phenotype	of	the	organ’s	donor.	
Moreover,	emphysema	does	not	develop.	
4.2. Respiratory problems in children
There	are	usually	no	clinical	symptoms	of	
the	disease	 in	 individuals	with	AAT	deficiency	
during	childhood	and	adolescence.	Factors	which	
may	accelerate	 the	development	of	 the	disease	
and	cause	symptoms	to	emerge	before	20	years	of	
age	include	exposure	to	tobacco	smoke,	frequent	
and	 severe	 lower	 respiratory	 tract	 infections,	
low	socioeconomic	status,	malnutrition	and	air	
pollution.	
Exposure	 to	passive	 smoking	 is	 a	 serious	
problem	negatively	affecting	pulmonary	 func-
tion	 in	pediatric	patients	with	AAT	deficiency.	
It	 is	 considered	one	of	 the	 factors	which	may	
accelerate	the	onset	of	emphysema	in	children.	
Nicotine	addiction	has	a	proven	detrimental	effect	
on	 life	expectancy	of	patients	with	severe	AAT	
deficiency,	shortening	the	life	of	smoking	patients	
with	this	deficiency	by	approximately	20	years.	
Therefore,	educational	programs	whose	purpose	
is	 to	eliminate	exposure	to	 tobacco	smoke	play	
an	 important	role	 in	care	of	patients	with	AAT	
deficiency.
Airway	 obstruction	 is	 often	 observed	 in	
patients	with	AAT	deficiency.	In	a	group	of	127	
PI*ZZ	patients	who	have	been	observed	 for	22	
consecutive	years	since	infancy,	15%	have	been	
diagnosed	with	asthma,	and	recurrent	wheezing	
occurred	 in	 29%.	However,	 the	 relationship	
between	AAT	deficiency	and	obstruction	of	the	
bronchial	 tree	 is	 inconstant	 and	a	 relation	of	
deficiency	phenotype	and	reduced	AAT	 levels	
to	increased	frequency	of	asthma	and	pollinosis	
in	children	has	not	been	successfully	shown.	At	
the	same	time,	increased	airway	hyperreactivity	
and	worse	parameters	of	pulmonary	function	in	
spirometry	are	noted	in	patients	with	asthma	and	
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AAT	deficiency.	Furthermore,	increased	frequen-
cy	of	lower	respiratory	tract	infections	in	infant	
carriers	of	PI*Z	and	PI*S	alleles	compared	 to	
children	with	normal	variants	has	been	observed.	
Prevention	of	respiratory	tract	infections	and	
reduction	of	air	pollution	are	important	elements	
in	care	of	children	with	AAT	deficiency.	Pneumo-
coccal	vaccination	and	annual	influenza	vaccina-
tion	are	recommended	for	these	patients.	In	case	
of	an	airway	obstruction	component,	bronchodi-
lators	(beta-2-	adrenomimetics,	anticholinergic)	
and	anti-inflammatory	drugs,	both	nonsteroidal	as	
well	as	inhaled	corticosteroids,	may	be	beneficial	
to	the	patients.	Antibiotics,	especially	macrolides	
which	are	also	anti-inflammatory,	are	recommen-
ded	for	individuals	with	AAT	deficiency	in	bron-
chitis	and	upper	respiratory	tract	infections.	So	
far,	a	single	case	of	effective	augmentation	therapy	
in	a	child	has	been	described.	This	therapy	is	not	
currently	recommended	for	children.
4.3. Pulmonary problems in adults 
4.3.1. Risk factors
It	is	estimated	that	in	1−5%	of	patients	with	
emphysema,	 it	 is	conditioned	by	inherited	AAT	
deficiency.	The	nature	of	relation	between	clinical	
consequences	of	deficiency	and	its	genetic	deter-
minants	has	not	been	explained.	The	character	
of	 the	mutation	does	not	determine	the	clinical	
picture	of	the	pulmonary	disease	and	individuals	
with	identical	deficiency	genotype	may	develop	
highly	varied	complications	within	respiratory	
system.	Tobacco	smoking	is	 the	most	 important	
environmental	 factor	determining	dynamics	of	
pulmonary	damage	and	development	of	symptoms,	
particularly	COPD.	It	is	a	key,	strong	risk	factor	of	
COPD	in	not	only	individuals	with	severe	inherited	
AAT	deficiency	(PI*ZZ,	PI*SZ,	PI*PI*Null/Null),	
but	also	carriers	of	one	deficiency	allele	(PI*MZ).	
However,	symptomatic	form	of	deficiency	is	not	
always	related	to	exposure	to	 tobacco	smoke	or	
occupational	factors.	
4.3.2. Clinical picture 
Emphysema,	 especially	with	 early	 onset	
(before	45	years	of	age)	and	a	symptomatic	form	
of	 chronic	obstructive	pulmonary	disease	 are	
the	most	common	complications	of	severe	AAT	
deficiency.	Asthma	marked	by	persistent	airway	
obstruction	 (atopic	and	non-atopic)	and	bron-
chiectasis	of	unclear	etiology	are	less	common.	
Occasionally	severe	AAT	deficiency	is	accompa-
nied	by	minimal	clinical	 symptoms,	also	with	
concomitant	obstructive	characteristics	in	pulmo-
nary	function	tests.	AAT	deficiency	may	promote	
recurrent	pneumothorax.
Symptomatology	 of	AAT	deficiency	 also	
includes	vasculitis,	mostly	 in	 the	 form	of	gra-
nulomatosis	with	polyangiitis	 (GPA)	 (formerly	
Wegener’s	granulomatosis)	with	the	presence	of	
anti-neutrophil	cytoplasmic	antibodies	(ANCAs)	
and	panniculitis.	
It	is	recommended	that	the	pulmonary	dise-
ase	developing	in	the	course	of	severe	AAT	defi-
ciency	be	treated	according	to	currently	accepted	
therapeutic	procedure	 for	a	particular	disease	
entity.	However,	the	necessity	of	particularly	ca-
reful	optimization	and	selection	of	drugs,	strict	
treatment	of	exacerbations	and	careful	observa-
tion	of	patients	due	to	high	risk	of	rapid	disease	
progression	should	be	taken	into	consideration.
4.3.3. Treatment of exacerbations  
of the pulmonary disease
Infective	exacerbations	of	COPD	are	a	par-
ticularly	important	clinical	problem	in	patients	
with	 severe	AAT	deficiency.	Much	 like	 in	 the	
classic	form	of	COPD,	their	frequency	is	related	
to	overall	health	and	the	degree	to	which	pulmo-
nary	ventilatory	reserve	is	limited.	However,	in	
patients	with	AAT	deficiency	episodes	of	exacer-
bation	last	significantly	longer,	which	is	due	to	
impairment	of	the	so-called	acute-phase	response,	
that	 is	mechanisms	of	 innate	 immunity	whose	
main	component	is	AAT.	Exacerbations	accelerate	
the	processes	of	destruction	of	lung	parenchyma.	
4.3.4. Symptomatic treatment of the pulmonary 
disease during the stable period
The	basic	methods	of	symptomatic	treatment	
of	chronic	diseases	marked	by	persistent	airway	
obstruction,	in	particular	COPD	in	the	course	of	
inherited	AAT	deficiency,	include:	
—		 strict	observance	of	 refraining	 from	active	
and	passive	tobacco	smoking,
—		 strict	avoidance	of	exposure	to	inhaled	irri-
tants	(in	the	workplace	and	at	home.,	
—		 prevention	 and	vigorous	 treatment	 of	 re-
spiratory	 tract	 infections;	annual	 influenza	
vaccination	 and	periodic	 pneumococcal	
vaccination	are	recommended,
—		 early	start	of	bronchodilator	therapy	in	case	
symptoms	of	airway	obstruction	occur,
—		 general	and	pulmonary	rehabilitation,	preparing	
a	written	exercise	program	is	recommended,	
—		 dietary	recommendations,	maintaining	opti-
mal	body	weight	is	indicated,
—	 home	oxygen	 therapy,	 in	accordance	with	
generally	accepted	indications,
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—		 lung	 transplantation,	 in	 accordance	with	
generally	accepted	indications.	
Augmentation therapy with human AAT
The	only	specific	treatment	method	for	severe	
AAT	deficiency	is	intravenous	AAT	substitution	
using	protein	obtained	from	the	serum	of	healthy	
individuals.	
Augmentation	therapy	has	been	accepted	by	
relevant	European	and	American	institutions	on	
three	grounds:
—		 proven	biochemical	effectiveness	of	intrave-
nous	AAT	preparations,	which	allow	to	achie-
ve	a	stable	increase	in	AAT	concentration	in	
the	serum	above	the	level	considered	protec-
tive	for	the	lungs	(>	11	µM	or	>	50	mg/dL	
determined	using	a	nephelometric	method);
—		 safety:	serious	adverse	effects	during	the	period	
of	administration	occur	with	a	frequency	close	
to	that	observed	in	the	placebo	group	(27%	vs.	
31%),	provided	generally	accepted	procedure	for	
intravenous	infusions	is	followed	and	contrain-
dications	for	augmentation	therapy	are	observed;
—		 there	are	no	other	specific	treatment	methods	
for	AAT	deficiency.
Augmentation	therapy	at	a	dose	of	60	mg/kg	
of	body	weight/week	is	recommended	for	patients	
with	severe	inherited	AAT	deficiency,	emphyse-
ma,	AAT	concentration	in	the	serum	≤	11	µmol/L,	
who	fulfill	the	following	spirometric	criteria:	FEV1 
after	bronchodilator	administration	=	30−65%	
predicted	or	annual	decline	 in	FEV1	value	≥	50	
mL/year.	Therapy	is	lifelong.	Smoking	is	a	factor	
precluding	the	patient	from	augmentation	therapy.	
There	 is	 limited	clinical	evidence	 for	AAT	
augmentation	therapy.	However,	significant	limi-
tations	of	conducting	clinical	trials	in	this	group	
of	patients	due	to	 its	relatively	small	size	have	
to	be	taken	into	consideration.	Likewise,	a	lack	
of	sufficiently	sensitive	biomarkers	which	would	
allow	to	reliably	monitor	the	dynamics	of	progres-
sion	of	emphysema	and	COPD	and	which	could	
constitute	an	adequate	endpoint	for	these	trials.	
Observational	 studies	 indicate	 that	 in	pa-
tients	with	moderate	to	very	severe	obstructive	
changes	(FEV1 =	31−65%	predicted)	intravenous	
AAT	substitution	slows	the	pulmonary	function	
decline	assessed	using	spirometry.	There	 is	no	
evidence	 that	 the	 therapy	significantly	affects	
mortality	rate	or	life	expectancy	of	patients	with	
AAT	deficiency.
In	a	recently	published	randomized,	place-
bo-controlled	 trial,	a	positive	 influence	on	 the	
dynamics	of	decline	in	FEV1	value	has	not	been	
observed;	however,	significant	modifying	influen-
ce	of	substitution	therapy	on	the	progression	of	
emphysema	in	patients	with	severe	AAT	deficien-
cy	has	been	confirmed.	Considerable	slowdown	
in	the	loss	of	lung	parenchyma	density	assessed	
using	computed	tomographic	lung	densitometry	
has	been	shown.	The	positive	effect	was	stronger	
the	earlier	AAT	augmentation	was	started.	
The	optimal	 form	of	medical	procedure	 is	
therefore	striving	for	the	earliest	possible	diagno-
sis	of	inherited	AAT	deficiency	and	early	start	of	
optimal	treatment,	including	substitution	therapy.
A	significant	effect	of	AAT	augmentation	on	
clinical	improvement	in	patients	with	mild	and	
extremely	severe	airway	obstruction	(FEV1	<	30%	
predicted)	has	not	been	shown.	AAT	augmenta-
tion	has	also	not	been	confirmed	to	be	an	effective	
prevention	against	emphysema	development	in	
healthy	adults	carrying	the	genotype	which	con-
ditions	severe	AAT	deficiency.	
High	cost	and	the	need	for	weekly	intrave-
nous	 infusions	are	 significant	 limiting	 factors	
for	long-term	administration	of	intravenous	AAT	
substitution	therapy.	
The	effectiveness	of	other	forms	of	AAT	substi-
tution	(administration	of	AAT	preparations	via	inha-
lation,	pharmacologically	supporting	AAT	secretion	
from	the	liver,	administration	of	other	neutrophil	
elastase	inhibitors)	has	not	been	confirmed	so	far.	
5. Summary
5.1. Main indications for diagnosing 
alpha-1 antitrypsin deficiency (Table 2)
Diagnosing	 inherited	 alpha-1	 antitrypsin	
deficiency	 is	 recommended	 in	 adult	 patients	
of	 either	 gender	with	 the	 following	disorders	
diagnosed:
—		 emphysema,	especially	with	early	onset	(be-
fore	45	years	of	age),
—	 symptomatic	 form	of	 chronic	obstructive	
pulmonary	disease,	 regardless	of	exposure	
to	tobacco	smoke,
—		 bronchial	 asthma	marked	 by	 persistent	
airway	obstruction,
—		 persistent	airway	obstruction	confirmed	by	
function	 tests	and	exposure	 to	occupatio-
nal	 factors	or	 tobacco	smoke,	 regardless	of	
whether	symptoms	occur,
—		 bronchiectasis	of	unclear	etiology,
—		 vasculitis	with	the	presence	of	c-ANCAs,
—		 liver	disease	of	unclear	etiology,
—		 necrotizing	panniculitis.
Testing	 for	 alpha-1	 antitrypsin	deficiency	
should	also	be	performed:
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Table 2. Main indications for diagnosing alpha-1 antitrypsin deficiency
Emphysema, especially with early onset (before 45 years of age),
Symptomatic form of chronic obstructive pulmonary disease, regardless of exposure to tobacco smoke,
Bronchial asthma marked by persistent airway obstruction
Persistent airway obstruction confirmed by function tests and exposure to occupational factors or tobacco smoke, regardless of whether 
symptoms occur
Bronchiectasis of unclear etiology
Vasculitis with the presence of c-ANCAs
Liver disease of unclear etiology
Necrotizing panniculitis
Family members of confirmed alpha-1 antitrypsin deficiency patients
Individuals with family history of one of the aforementioned disorders
—		 in	 family	members	 of	 confirmed	alpha-1	
antitrypsin	deficiency	patients,
—		 in	individuals	with	family	history	of	one	of	
the	aforementioned	disorders.
5.2. Laboratory normal levels 
Measurement	of	AAT	concentration	in	blo-
od	serum/plasma	is	an	initial	test	performed	for	
individuals	with	 suspected	deficiency	of	 this	
inhibitor.	
AAT	concentration	can	be	expressed	in	mil-
ligrams	per	deciliter	 (mg/dL)	or	millimoles	per	
liter	(µmol/L	or	µM).	
Normal	 levels	of	AAT	concentration	 in	 the	
serum	of	healthy	individuals	are:
—		 when	using	an	 immunonephelometric	me-
thod	—	103−200	mg/dL	(20−39	µM),	
—		 when	using	rocket	 immunoelectrophoresis	
—	150−330	mg/dL.
AAT	level	<	100	mg/dL	should	be	an	indica-
tion	for	further	qualitative	tests.
Threshold	(protective)	concentration	of	AAT	
is	11	µmol/L,	which	corresponds	to:
—		 50	mg/dL	for	immunonephelometric	method,
—		 80	mg/dL	for	rocket	immunoelectrophoresis.
5.3. Addresses of diagnostic laboratories
Department	of	Genetics	and	Clinical	Immunology
Institute	of	Tuberculosis	and	Lung	Diseases
ul.	Płocka	26,	01−138	Warsaw
Head	of	the	Department:	prof.	dr	hab.	med.	Joanna	
Chorostowska-Wynimko
Person	responsible	for	testing:	mgr	Aneta	Zdral
Tel.	+48	22 431	21	58
Fax.	+48	22 431	23	58
e-mail:	immuno@igichp.edu.pl	
Institute	of	Molecular	Biology	and	Clinical	Ge-
netics
II	Chair	 of	 Internal	Medicine	of	 the	Medical	
College
Jagiellonian	University
ul.	Skawińska	8,	31−066	Cracow
Head	of	the	Laboratory:	prof.	dr	hab.	med.	Marek	
Sanak
Person	responsible	 for	 testing:	dr	med.	Marcin	
Kaczor
Tel.	+48	12 430	52	66	ext.	238,	303
Fax.	+48	12 430	52	03
e-mail:	aat1@mp.pl
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